Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome

被引:86
作者
Allen, Richard P. [1 ]
机构
[1] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21224 USA
关键词
dopamine; epidemiology; iron; restless legs syndrome; SUSCEPTIBILITY LOCUS; SYNDROME RLS; DRUG-NAIVE; BRAIN IRON; NORMAL IPT; DIAGNOSIS; DOPAMINE; TRANSFERRIN; PREVALENCE; EPIDEMIOLOGY;
D O I
10.1016/j.amjmed.2006.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Restless legs syndrome (RLS) can occur as a primary disorder, with no apparent cause other than a possible genetic predisposition, or as a secondary condition, most commonly related to iron deficiency, pregnancy, or end-stage renal disease. Recent studies have identified 2 different phenotypes of RLS based on age at onset of symptoms. Persons whose RLS symptoms start at an earlier age (< 45 years) are more likely to have a family history of RLS and tend to have a more slowly progressive development of the disorder compared with individuals who have later onset of symptoms. In the past, our ability to determine either prevalence or population factors associated with increased occurrence of RLS has been limited. However, 4 different diagnostic criteria have been established. Familiarity with diagnostic criteria and clinical characteristics are essential for diagnosis and appropriate treatment, if required. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:S13 / S21
页数:9
相关论文
共 46 条
[21]   Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome [J].
Eisensehr, I ;
Wetter, TC ;
Linke, R ;
Noachtar, S ;
Von Lindeiner, H ;
Gildehaus, FJ ;
Trenkwalder, C ;
Tatsch, K .
NEUROLOGY, 2001, 57 (07) :1307-1309
[22]   Iron deficiency decreases dopamine D1 and D2 receptors in rat brain [J].
Erikson, KM ;
Jones, BC ;
Hess, EJ ;
Zhang, Q ;
Beard, JL .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2001, 69 (3-4) :409-418
[23]   THE INFLUENCE OF OPIOID RECEPTOR SUBTYPES ON THE PROCESSING OF NOCICEPTIVE INPUTS IN THE SPINAL DORSAL HORN OF THE CAT [J].
FLEETWOODWALKER, SM ;
HOPE, PJ ;
MITCHELL, R ;
ELYASSIR, N ;
MOLONY, V .
BRAIN RESEARCH, 1988, 451 (1-2) :213-226
[24]  
Garcia-Borreguero D, 2004, SLEEP, V27, P669
[25]   Role of dopamine receptor agonists in the treatment of restless legs syndrome [J].
Happe, S ;
Trenkwalder, C .
CNS DRUGS, 2004, 18 (01) :27-36
[26]   Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study [J].
Hening, W ;
Walters, AS ;
Allen, RP ;
Montplaisir, J ;
Myers, A ;
Ferini-Strambi, L .
SLEEP MEDICINE, 2004, 5 (03) :237-246
[27]   An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder [J].
Hening, WA ;
Allen, RP ;
Earley, CJ ;
Picchietti, DL ;
Silber, MH .
SLEEP, 2004, 27 (03) :560-583
[28]   EVIDENCE FOR A DOPAMINERGIC PATHWAY IN THE RAT DESCENDING FROM THE A11-CELL GROUP TO THE SPINAL-CORD [J].
HOKFELT, T ;
PHILLIPSON, O ;
GOLDSTEIN, M .
ACTA PHYSIOLOGICA SCANDINAVICA, 1979, 107 (04) :393-395
[29]   Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome [J].
Kushida, Clete A. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (1A) :4-12
[30]   SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep [J].
Michaud, M ;
Soucy, JP ;
Chabli, A ;
Lavigne, G ;
Montplaisir, J .
JOURNAL OF NEUROLOGY, 2002, 249 (02) :164-170